Authors Note: The authors recognize the fast-evolving nature of GLP-1 research and trends and will endeavour to ensure the article remains current with emerging GLP-1 RA data.
By Product: Ozempic dominates, Tirzepatide products growing fastest Ozempic (semaglutide 0.5mg/1mg/2mg weekly subcutaneous injection) dominated the GLP-1 receptor agonist market with approximately 35.12% market share in 2025, driven by its combination of robust clinical efficacy data, early market entry, broad diabetes label, established prescriber relationships, and expanded off-label use for weight management before Wegovy's commercial scale-up
While the risk of developing PD is reduced with the use of calcium channel blockers to control hypertension, the positive influences of ACE inhibitors, -blockers, and ARBs are not clear (114)
Essential for accurate dosing and safe administration
Anlogos GLP-1/GIP Obesidad con comorbilidades metablicas (DM2, dislipemia, Hgado graso) Pacientes con alto riesgo quirrgico o que rechazan procedimientos Candidatos a tratamiento crnico con control mdico
